



EVERY DAY 3000

PEOPLE GLOBALLY DIE FROM ACUTE BLOOD LOSS

44% in military operations

11% in domestic safety incidents

2

26% as a resulte of a traffic accident

4

19% due to emerdencies and disasters





GLOBAALY KNOWN HEMOSTATIC PRODUCTS PRESENTLY USED TO STOP ACUTE BLOOD LOSS

+++Overall effectivenss

+Effectivenss in hypocoagulation

Anti-bacterial effect-

-Adverse effects

QUIKCLOT

+++Overall effectivenss

+Effectivenss in hypocoagulation

Anti-bacterial effect+

-Adverse effects

CELOX

+++Overall effectivenss

+Effectivenss in hypocoagulation

Anti-bacterial effect-

Adverse effects++

HAEMOSTOP



Topical hemostatic produce developed and manufactured in Russia using electrical molding technology





Reduces first aid time



presentation
z-folded bandage up to 3 m long
nanofiber material structure



basic active angredient is chitosan in form of nanofibers



For temporary emergency control of extral arterial and venous bleedind



Reduces blood lossm risk of bleeding relapse and lethality



HEMOFLEX MECHANISM OF ACTION






produce contacts blood

2

red blood cells are attracted to Hemoflex fibers due to the opposite charge of blood cells and chitosan fibers



3

change of red blood cells surface potential ,formation of gel-like clot

4

vessel damage zone closure and bleeding arrest



HEMOFLEXADVANTAGES

sample use easy to unpack atraumatic separation


Use of nanofibers
helps increase hemostatic effect

effect and does not cause thermal burn

Z-fold bandage fast use

Manufactured from vegetable feedstock does not contain animal protein







PRECLINICAL

CLINICAL

Model

External arterial and venous bleeding standard injury of the thigh with full transection of femoral artery and vein swine

Result

Use of Hemoflex helped reduce wound bleeding time and blood loss volume, confirming pronounced hemostatic effect


Model

St.Petersbure, Pavlov First Saint Petersburg state Medical University 14patients aged from 51 to 82, control of arterial, venous and capillary bleeding in surgical access to pelvic area during operation for removal of pelvic hernia

Result

In all cases, hemostatic effect was achieved, no bleeding relapse after Hemoflex separation from the wound occurred, adverse event were absent

HEMOFLEX TESTING



Uses of Hemoflex

In the medical field

It is used to secure medical devices in hospitals

It is used in surgical operations to ensure effective control of bleeding



It is used in first aid in ambulances and hospital emergency rooms

It is used in medical research to study its effect on bleeding

Uses of Hemoflex

It is used in the industrial field to stop bleeding in .critical injury cases

Inotherfields

It is used in homes and restaurants as first aid in cases of injury and bleeding



It is an essential component in the first aid kit of every citizen's car for emergencies

It is an essential component in the clinics of schools and universities



CONCLUSIONS



Today's global market of chitosan-based hemostatic products is dominated by the two major manufacturers: MedTrade Products Ltd (UK) and HemCon Medical Technologies Inc. (USA). These market leaders manufacture medical products for temporary control of external bleeding in form of powders (Celox Granules) and non-woven materials Celox RAPID Gauze, HemCon)
.(ChitoGauze R



Preclinical and clinical tests of
Hemoflex have demonstrated high
hemostatic effectiveness and improved
hemostasis stability versus
counterparts. Innovative technology for
processing of Hemoflex® biomedical
polymers exceeds foreign counterparts
.in terms of effectiveness



Performance tests have shown that
Hemoflex reliably improves
effectiveness of temporary control of
,external arterial and venous bleeding
does not cause exothermal reaction in
contact with body tissues, does not
require additional preparation and is
.easy to use

